Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Transpl Infect Dis ; 17(2): 297-302, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25651934

ABSTRACT

In recent years, black fungi have been increasingly reported as causing opportunistic infections after solid organ transplantation. Here, we report a case of insidious, relentless, and multifocal Exophiala xenobiotica infection in a kidney transplant recipient that eventually required multiple surgical excisions along with oral and intravenous antifungal combination therapy using liposomal amphotericin B and posaconazole. We compare the present case with all previously reported cases of Exophiala infection after kidney transplantation.


Subject(s)
Exophiala , Graft Rejection/prevention & control , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Kidney Transplantation , Opportunistic Infections/etiology , Phaeohyphomycosis/etiology , Aged , Female , Humans , Opportunistic Infections/immunology , Opportunistic Infections/pathology , Phaeohyphomycosis/immunology , Phaeohyphomycosis/pathology , Transplant Recipients
2.
Am J Transplant ; 14(11): 2515-25, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25155294

ABSTRACT

Pretransplant donor biopsy (PTDB)-based marginal donor allocation systems to single or dual renal transplantation could increase the use of organs with Kidney Donor Profile Index (KDPI) in the highest range (e.g. >80 or >90), whose discard rate approximates 50% in the United States. To test this hypothesis, we retrospectively calculated the KDPI and analyzed the outcomes of 442 marginal kidney transplants (340 single transplants: 278 with a PTDB Remuzzi score<4 [median KDPI: 87; interquartile range (IQR): 78-94] and 62 with a score=4 [median KDPI: 87; IQR: 76-93]; 102 dual transplants [median KDPI: 93; IQR: 86-96]) and 248 single standard transplant controls (median KDPI: 36; IQR: 18-51). PTDB-based allocation of marginal grafts led to a limited discard rate of 15% for kidneys with KDPI of 80-90 and of 37% for kidneys with a KDPI of 91-100. Although 1-year estimated GFRs were significantly lower in recipients of marginal kidneys (-9.3, -17.9 and -18.8 mL/min, for dual transplants, single kidneys with PTDB score<4 and =4, respectively; p<0.001), graft survival (median follow-up 3.3 years) was similar between marginal and standard kidney transplants (hazard ratio: 1.20 [95% confidence interval: 0.80-1.79; p=0.38]). In conclusion, PTDB-based allocation allows the safe transplantation of kidneys with KDPI in the highest range that may otherwise be discarded.


Subject(s)
Graft Survival , Kidney , Tissue Donors , Adult , Aged , Biopsy , Female , Humans , Kidney/pathology , Male , Middle Aged
4.
Minerva Anestesiol ; 76(11): 961-4, 2010 Nov.
Article in English | MEDLINE | ID: mdl-21102392

ABSTRACT

We report on a patient with biliary sepsis due to Vancomycin-resistant Enterococcus faecium (VRE) treated with linezolid (LNZ), who had both hepatic failure and acute kidney injury requiring daily sustained low-efficiency dialysis (SLED), a new intermittent, prolonged diffusive modality of renal replacement therapy for ICU patients. Following cholecystostomy and peritoneal drain insertion, serum, bile and peritoneal fluid serial samples were simultaneously collected for LNZ concentration measurement (chromatography/mass spectrometry). Unusually high serum antibiotic levels (20 mg/L or more) were achieved as early as 36 hours since the start of LNZ administration, owing to relatively low hepatic clearance. Serum LNZ leveled off after commencing SLED, apparently reaching steady state levels. The lowest values of Cmin in bile was 5.86 mg/L; the average serum and bile AUC0-12 over the observation period were 204 mg/L*h and 276 mg/L*h, with a AUC0-24/MIC ratio of 227 h and 307 h, respectively. The excellent biliary pharmacodynamic exposure suggests that standard-dose LNZ might represent a valuable choice in severe biliary infection, even in the presence of hepatic failure, when the patients receive highly efficient modalities of renal replacement therapy.


Subject(s)
Acetamides/blood , Acetamides/therapeutic use , Acute Kidney Injury/drug therapy , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/therapeutic use , Biliary Tract Diseases/drug therapy , Liver Failure/drug therapy , Oxazolidinones/blood , Oxazolidinones/therapeutic use , Renal Dialysis , Sepsis/drug therapy , Sepsis/metabolism , APACHE , Acute Kidney Injury/metabolism , Aged , Biliary Tract Diseases/metabolism , Cholecystectomy , Enterococcus faecium , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiology , Humans , Linezolid , Liver Failure/metabolism , Male , Vancomycin Resistance
SELECTION OF CITATIONS
SEARCH DETAIL